In 2009, work by Olive and colleagues in PDAC mouse models found that targeting SHH signalling, a known driver of desmoplasia in pancreatic cancer [80], could deplete the tumour stroma, improve tumour vascularity and enhance delivery of standard-of-care gemcitabine into tumours, resulting in increased survival [81]. This evidence concerns the gene SHH and neoplasm.